fda compounding glp-1 enforcement news november 2025 Crackdown Novo pressures GLP-1 compounders as

DN is associated with gut dysbiosischaracterized by reduced microbial diversity, depletion of beneficial short-chain fatty acid (SCFA)-producing bacteria, and proliferation of opportunistic pathogens

The program will operate outside of the standard Part D program, so individual Part D plans don't need to take any actioneligible beneficiaries can access these drugs automatically

Note: If you experience signs of a severe allergic reaction, such as swelling or trouble breathing, seek emergency medical care immediately

[25] Research [edit] Most studies investigating alpha-glucosidase and alpha-amylase inhibitory activity use acarbose as reference

Modifying effects of anti-insulin serum and of total insulin dosage

Independent Wellness partners with FDA-compliant compounding pharmacies that meet strict manufacturing and safety standards